A phase I clinical trial to evaluate the pharmacokinetics, toxicity and dosimetry of 111-indium-labeled human epidermal growth factor in patients with metastatic breast cancer

Documents similaires

• Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer.
  par: Vallis, K, et autres
  Publié: (2014)
• Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
  par: Reilly, R, et autres
  Publié: (2006)
• A phase I trial of In-111-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer
  par: Vallis, K, et autres
  Publié: (2008)
• A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
  par: Reilly, R, et autres
  Publié: (2004)
• Amplified delivery of indium-111 to EGFR-positive human breast cancer cells.
  par: Wang, J, et autres
  Publié: (2001)